Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:42 PM
Ignite Modification Date:
2025-12-24 @ 2:42 PM
NCT ID:
NCT04987359
Eligibility Criteria:
Inclusion Criteria:
* Ability to provide informed consent before any trial-related activities
* History of any malignancy
* Completion of cancer-directed therapy (e.g., surgery, chemotherapy, and radiotherapy) prior to enrollment (patients receiving ongoing endocrine or targeted therapy are eligible to participate)
* No evidence of residual or recurrent cancer under active treatment
* Age ≥18 years
* Body mass index (BMI) ≥30 kg/m2 or BMI ≥27 kg/m2 with one or more treated or untreated weight-related coexisting conditions
* Willing to be randomized
* Allow the collection and storage of biospecimens and data for future use
Exclusion Criteria:
* Engaging in ≥3 purposeful exercise sessions per week, on average, over the past 12 weeks
* Significant purposeful weight loss (\>11 kg) within the past 12 weeks
* Current use of medications or devices for the purpose of weight loss
* Metabolic or bariatric surgery within the last year
* Cardiovascular, respiratory, or musculoskeletal disease that would prohibit participation in an exercise and weight loss program
* Currently pregnant, breastfeeding, or planning to become pregnant with the next 12 weeks
* Psychiatric disorders or conditions that would preclude participation in the study intervention
* Any other condition which, in the opinion of the investigator, may impede testing of the study hypothesis or make it unsafe to engage in the study
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04987359
Study Brief:
Protocol Section:
NCT04987359